vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and UNITED STATES LIME & MINERALS INC (USLM). Click either name above to swap in a different company.

UNITED STATES LIME & MINERALS INC is the larger business by last-quarter revenue ($87.9M vs $77.6M, roughly 1.1× Bioceres Crop Solutions Corp.). UNITED STATES LIME & MINERALS INC runs the higher net margin — 34.7% vs -9.6%, a 44.3% gap on every dollar of revenue. On growth, UNITED STATES LIME & MINERALS INC posted the faster year-over-year revenue change (9.8% vs -16.8%). Over the past eight quarters, UNITED STATES LIME & MINERALS INC's revenue compounded faster (10.8% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

United States Lime & Minerals Inc is a leading US-based natural resources enterprise that produces high-calcium lime, dolomitic lime, limestone and related mineral products. Its core client segments cover infrastructure construction, steel manufacturing, agricultural soil amendment, environmental emission control and industrial processing, serving customers across North America.

BIOX vs USLM — Head-to-Head

Bigger by revenue
USLM
USLM
1.1× larger
USLM
$87.9M
$77.6M
BIOX
Growing faster (revenue YoY)
USLM
USLM
+26.7% gap
USLM
9.8%
-16.8%
BIOX
Higher net margin
USLM
USLM
44.3% more per $
USLM
34.7%
-9.6%
BIOX
Faster 2-yr revenue CAGR
USLM
USLM
Annualised
USLM
10.8%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
USLM
USLM
Revenue
$77.6M
$87.9M
Net Profit
$-7.4M
$30.5M
Gross Margin
46.8%
48.0%
Operating Margin
9.3%
41.0%
Net Margin
-9.6%
34.7%
Revenue YoY
-16.8%
9.8%
Net Profit YoY
-20.2%
13.2%
EPS (diluted)
$-0.12
$1.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
USLM
USLM
Q4 25
$87.9M
Q3 25
$77.6M
$102.0M
Q2 25
$91.5M
Q1 25
$60.6M
$91.3M
Q4 24
$98.8M
$80.1M
Q3 24
$93.3M
$89.4M
Q2 24
$76.5M
Q1 24
$84.0M
$71.7M
Net Profit
BIOX
BIOX
USLM
USLM
Q4 25
$30.5M
Q3 25
$-7.4M
$38.8M
Q2 25
$30.8M
Q1 25
$-1.6M
$34.1M
Q4 24
$605.2K
$27.0M
Q3 24
$-6.2M
$33.4M
Q2 24
$26.1M
Q1 24
$9.8M
$22.4M
Gross Margin
BIOX
BIOX
USLM
USLM
Q4 25
48.0%
Q3 25
46.8%
51.2%
Q2 25
45.8%
Q1 25
39.4%
50.6%
Q4 24
42.0%
44.3%
Q3 24
40.2%
48.2%
Q2 24
45.5%
Q1 24
50.8%
42.7%
Operating Margin
BIOX
BIOX
USLM
USLM
Q4 25
41.0%
Q3 25
9.3%
45.3%
Q2 25
39.0%
Q1 25
1.5%
43.7%
Q4 24
14.5%
38.8%
Q3 24
2.5%
42.6%
Q2 24
39.1%
Q1 24
15.7%
35.9%
Net Margin
BIOX
BIOX
USLM
USLM
Q4 25
34.7%
Q3 25
-9.6%
38.0%
Q2 25
33.7%
Q1 25
-2.6%
37.4%
Q4 24
0.6%
33.7%
Q3 24
-6.6%
37.3%
Q2 24
34.0%
Q1 24
11.6%
31.3%
EPS (diluted)
BIOX
BIOX
USLM
USLM
Q4 25
$1.06
Q3 25
$-0.12
$1.35
Q2 25
$1.07
Q1 25
$-0.02
$1.19
Q4 24
$0.00
$-2.20
Q3 24
$-0.10
$1.16
Q2 24
$0.91
Q1 24
$0.14
$3.92

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
USLM
USLM
Cash + ST InvestmentsLiquidity on hand
$15.5M
$371.1M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$288.3M
$630.8M
Total Assets
$734.9M
$681.0M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
USLM
USLM
Q4 25
$371.1M
Q3 25
$15.5M
$349.5M
Q2 25
$319.9M
Q1 25
$38.5M
$300.6M
Q4 24
$29.2M
$278.0M
Q3 24
$32.3M
$255.0M
Q2 24
$222.5M
Q1 24
$16.4M
$207.0M
Total Debt
BIOX
BIOX
USLM
USLM
Q4 25
$0
Q3 25
$0
Q2 25
$0
Q1 25
$0
Q4 24
$0
Q3 24
$0
Q2 24
$0
Q1 24
$0
Stockholders' Equity
BIOX
BIOX
USLM
USLM
Q4 25
$630.8M
Q3 25
$288.3M
$602.3M
Q2 25
$563.3M
Q1 25
$345.0M
$532.2M
Q4 24
$346.3M
$497.7M
Q3 24
$346.0M
$474.2M
Q2 24
$441.1M
Q1 24
$348.5M
$415.3M
Total Assets
BIOX
BIOX
USLM
USLM
Q4 25
$681.0M
Q3 25
$734.9M
$652.8M
Q2 25
$607.4M
Q1 25
$798.2M
$585.3M
Q4 24
$835.2M
$543.2M
Q3 24
$827.3M
$521.8M
Q2 24
$484.2M
Q1 24
$836.1M
$464.0M
Debt / Equity
BIOX
BIOX
USLM
USLM
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
USLM
USLM
Operating Cash FlowLast quarter
$14.4M
$45.6M
Free Cash FlowOCF − Capex
$25.7M
FCF MarginFCF / Revenue
29.2%
Capex IntensityCapex / Revenue
22.6%
Cash ConversionOCF / Net Profit
1.49×
TTM Free Cash FlowTrailing 4 quarters
$102.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
USLM
USLM
Q4 25
$45.6M
Q3 25
$14.4M
$45.9M
Q2 25
$34.0M
Q1 25
$23.3M
$39.4M
Q4 24
$-5.4M
$38.6M
Q3 24
$5.2M
$39.0M
Q2 24
$21.2M
Q1 24
$-17.4M
$27.2M
Free Cash Flow
BIOX
BIOX
USLM
USLM
Q4 25
$25.7M
Q3 25
$31.3M
Q2 25
$20.8M
Q1 25
$24.6M
Q4 24
$27.6M
Q3 24
$33.9M
Q2 24
$16.8M
Q1 24
$20.3M
FCF Margin
BIOX
BIOX
USLM
USLM
Q4 25
29.2%
Q3 25
30.7%
Q2 25
22.7%
Q1 25
26.9%
Q4 24
34.4%
Q3 24
37.9%
Q2 24
21.9%
Q1 24
28.4%
Capex Intensity
BIOX
BIOX
USLM
USLM
Q4 25
22.6%
Q3 25
14.4%
Q2 25
14.5%
Q1 25
16.3%
Q4 24
13.8%
Q3 24
5.8%
Q2 24
5.7%
Q1 24
9.5%
Cash Conversion
BIOX
BIOX
USLM
USLM
Q4 25
1.49×
Q3 25
1.18×
Q2 25
1.10×
Q1 25
1.16×
Q4 24
-8.85×
1.43×
Q3 24
1.17×
Q2 24
0.81×
Q1 24
-1.78×
1.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons